Literature DB >> 34419519

Diagnosis and Management of Osteoporosis in Advanced Kidney Disease: A Review.

Charles Ginsberg1, Joachim H Ix2.   

Abstract

Osteoporosis and fractures are common in persons with advanced chronic kidney disease (CKD) and on maintenance dialysis. Although the diagnosis of osteoporosis in this population can be difficult, imaging, especially with dual-energy x-ray absorptiometry (DXA), is helpful in identifying persons with CKD at the highest risk of fracture. Although blood biomarkers including parathyroid hormone and bone-specific alkaline phosphatase concentrations can aid in assessing bone turnover state, bone biopsy remains the gold standard in determining bone turnover in persons with advanced kidney disease and osteoporosis. With the increasing armamentarium of osteoporosis drugs, it now may be possible to prevent many fractures in advanced CKD. Unfortunately, data on these drugs are limited in persons with advanced CKD. Clinicians, aided by advances in imaging, biomarkers, and bone biopsy can now use these novel agents to target bone turnover abnormalities such as adynamic bone disease and high bone turnover disease. This review will discuss the most recent literature surrounding the diagnosis, management, and monitoring of osteoporosis and fractures in persons with advanced CKD or on maintenance dialysis.
Copyright © 2021 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Abaloparatide; antiresorptive medications; bone biopsy; bone mineral density (BMD); bone turnover marker (BTM); calcimimetics; chronic kidney disease–mineral and bone disorder (CKD-MBD); dialysis; end-stage renal disease (ESRD); fragility fractures; imaging; osteoporosis; review; teriparatide; vitamin D receptor agonists

Mesh:

Substances:

Year:  2021        PMID: 34419519     DOI: 10.1053/j.ajkd.2021.06.031

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  4 in total

Review 1.  Alkaline Phosphatase: An Old Friend as Treatment Target for Cardiovascular and Mineral Bone Disorders in Chronic Kidney Disease.

Authors:  Mathias Haarhaus; Giuseppe Cianciolo; Simona Barbuto; Gaetano La Manna; Lorenzo Gasperoni; Giovanni Tripepi; Mario Plebani; Maria Fusaro; Per Magnusson
Journal:  Nutrients       Date:  2022-05-19       Impact factor: 6.706

Review 2.  Use of Artificial Intelligence to Identify New Mechanisms and Approaches to Therapy of Bone Disorders Associated With Chronic Kidney Disease.

Authors:  Adam E Gaweda; Eleanor D Lederer; Michael E Brier
Journal:  Front Med (Lausanne)       Date:  2022-03-25

3.  Relationship between indices of circulating blood cells and bone homeostasis in osteoporosis.

Authors:  Yuan Li; Weimin Hao; Jianming Guan; Bo Li; Li Meng; Shuangjiao Sun; Tianyuan Sheng; Shuangxi Dong; Qian Zhou; Mingjie Liu; Zhongkai Zhang; Tao Shen; Yuemao Shen; Baobing Zhao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-05       Impact factor: 6.055

4.  Efficacy and safety of radiofrequency ablation versus parathyroidectomy for secondary hyperparathyroidism in dialysis patients: a single-center retrospective study.

Authors:  Mian Ren; Danna Zheng; Juan Wu; Yueming Liu; Chengzhong Peng; Wei Shen; Bo Lin
Journal:  Sci Rep       Date:  2022-06-18       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.